1. Approval-Centric Thinking – Case: Biotech for a rare disease drug
Case: A rare disease drug (analogous to Ultragenyx-type assets) received PMDA approval.
Expected price (global benchmark): JPY 120M/year
Actual NHI price: JPY 70M/year (~-40%)
Sales forecast: JPY 10B → Actual: JPY 5–6B
Root Cause: Overreliance on approval milestone and global pricing.
Solution: Parallel pricing strategy + early Chuikyo scenario modeling.
2. Misunderstanding Pricing Mechanism – Case: oncology product (EU Pharma)
Case: EU oncology drug expected premium pricing via value argument.
Outcome: Classified under similar efficacy comparison → limited premium.
Price gap: Expected +30% premium → Actual +5%
Root Cause: Misunderstandings of rule-based pricing system.
Solution: Pre-classification of pricing method.
3. Overreliance on Global Pricing – Case: CAR-T Therapy
Case: US price ~$400k; Japan expectation aligned.
Outcome: FPA adjustment led to ~30–50% discount vs US.
Root Cause: Anchoring on US WAC.
Solution: Japan-specific price modeling with downside scenarios.
4. Evidence Gap – Case: CNS Drug
Case: Strong global data but no Japanese RWD.
Adoption lag: 2–3 years vs expectation.
Root Cause: Lack of local evidence.
Solution: Early RWD + subgroup analysis.
5. Weak KOL Engagement – Case: Rare Disease Therapy
Case: Competitor engaged Japanese KOLs early.
Outcome: Guideline inclusion delayed by ~3 years.
Root Cause: Late KOL strategy.
Solution: Early scientific engagement.
6. Lack of Local Partner Strategy – Case: mid-size Biotech
Case: Solo entry → pricing delay ~12 months.
Revenue loss: ~JPY 2–3B opportunity cost.
Root Cause: No local execution capability.
Solution: Partner with Japan-experienced firm.
7. Organizational Misalignment – Case: Global HQ vs Japan
Case: HQ pricing expectation unrealistic.
Outcome: Internal conflict → delayed decisions.
Root Cause: HQ-driven strategy.
Solution: Empower Japan affiliate.
8. Timing Issues – Case: Late Market Access
Case: Pricing prep post-approval.
Delay: ~12–18 months to listing.
Root Cause: Late start.
Solution: Start at Phase II.
9. Post-Listing Risk – Case: Ultra-rare disease drug
Case: Estimated price: JPY 75–95M/year (base ~85–90M)
Risk: Market expansion repricing → potential 10–20% drop
Root Cause: Ignoring lifecycle pricing risk.
Solution: Continuous price strategy.
10. Summary – From failure to Solution
Failure: Approval-centric / Global assumption
Root Cause: Structural misunderstanding of Japan system
Solution: Japan-specific integrated strategy (KOL + Evidence + Pricing)
